AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38237090 — intervention group
Group type: COMPARATOR
Intervention: Prepandemic controls
Number of subjects: 105
Study 38237090 — intervention group
Group type: COMPARATOR
Intervention: Long-COVID patients vs pandemic controls
Number of subjects: 105
Study 38237090 — intervention group
Group type: COMPARATOR
Intervention: Long-COVID patients vs prepandemic controls
Number of subjects: 105
Study 38237090 — intervention group
Group type: COMPARATOR
Intervention: Pandemic controls vs prepandemic controls
Number of subjects: 105
Study 38237263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror movement therapy ankle exercises for 15 minutes daily
Number of subjects: 15
Study 38237263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror movement therapy ankle exercises for 30 minutes daily
Number of subjects: 15
Study 38237263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror movement therapy ankle exercises for 50 minutes daily
Number of subjects: 15
Study 38237263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror movement therapy ankle exercises for 40 minutes daily
Number of subjects: 15
Study 38237263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror movement therapy ankle exercises for 35 minutes daily
Number of subjects: 15
Study 38237263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror movement therapy ankle exercises (various doses)
Number of subjects: 15
Study 38237373 — intervention group
Group type: EXPERIMENTAL
Intervention: Surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, once every 3 weeks)
Number of subjects: 40
Study 38237620 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine 5 mg orally twice daily for 14 days
Number of subjects: 44
Study 38237620 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 14 days
Number of subjects: 44
Study 38237621 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant FOLFIRINOX
Number of subjects: 140
Study 38237621 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 140
Study 38237636 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF < 45%
Number of subjects: 292
Study 38237636 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPSE < 17 mm
Number of subjects: 292
Study 38237674 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ERP) delivered via video telehealth (VTH) for up to 16 sessions
Number of subjects: 160
Study 38237674 — intervention group
Group type: COMPARATOR
Intervention: Stress management training control delivered via video telehealth (VTH)
Number of subjects: 160
Study 38237675 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg daily for 7 days followed by 5 mg/kg daily for 7 days)
Number of subjects: 200
Study 38237675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 38237675 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 200
Study 38237696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tradipitant 85 mg
Number of subjects: 201
Study 38237696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 38237796 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Point Pacing (MPP)
Number of subjects: 51
Study 38237796 — intervention group
Group type: COMPARATOR
Intervention: Standard single-site pacing (STD)
Number of subjects: 51
Study 38237898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing dysglycaemia defined by HbA1c at 4 months
Number of subjects: 348
Study 38237898 — intervention group
Group type: COMPARATOR
Intervention: HbA1c levels <5.7%
Number of subjects: 348
Study 38237898 — intervention group
Group type: COMPARATOR
Intervention: HbA1c levels ≥5.7%
Number of subjects: 348
Study 38237898 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes (pre- and newly diagnosed, n=16) excluded
Number of subjects: 348
Study 38238052 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified intubation protocol (M group)
Number of subjects: 200
Study 38238052 — intervention group
Group type: COMPARATOR
Intervention: Conventional intubation process (C group)
Number of subjects: 200
Study 38238052 — intervention group
Group type: EXPERIMENTAL
Intervention: Early resumption of oral intake (E group)
Number of subjects: 200
Study 38238052 — intervention group
Group type: COMPARATOR
Intervention: Delayed resumption of oral intake (D group)
Number of subjects: 200
Study 38238050 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) after interhospital transfer
Number of subjects: 49
Study 38238057 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health campaigns/antenatal care adaptation related to modifiable risk factors for late stillbirth.
Number of subjects: 0
Study 38238057 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 38238055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal irinotecan (75 mg) with concomitant mFOLFOX4 and bevacizumab
Number of subjects: 85
Study 38238058 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartMom messages
Number of subjects: 0
Study 38238058 — intervention group
Group type: COMPARATOR
Intervention: Messages addressing general topics related to pregnancy without direction for behaviour change
Number of subjects: 0
Study 38238060 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA air filtration
Number of subjects: 160
Study 38238060 — intervention group
Group type: COMPARATOR
Intervention: Sham air purifiers
Number of subjects: 160
Study 38238170 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMPlified LaYered consent process
Number of subjects: 0
Study 38238170 — intervention group
Group type: COMPARATOR
Intervention: Standard informed consent forms (ICFs)
Number of subjects: 0
Study 38238175 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Zhiwang decoction (MZWD) combined with methotrexate (MTX)
Number of subjects: 150
Study 38238175 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 150
Study 38238182 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Exercise
Number of subjects: 117
Study 38238182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle
Number of subjects: 117
Study 38238182 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Structured Exercise and Lifestyle
Number of subjects: 117
Study 38238182 — intervention group
Group type: COMPARATOR
Intervention: Non-responders to initial treatment
Number of subjects: 117
Study 38238194 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine needle injection (EUS-FNI) of large surface area microparticle paclitaxel (LSAM-PTX) at a concentration of 15 mg/mL, with a mean of 4 doses administered (mean dose/cyst: 73 ± 31 mg)
Number of subjects: 5
Study 38238230 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent cling film applied over the lower face
Number of subjects: 25
Study 38238230 — intervention group
Group type: COMPARATOR
Intervention: No transparent cling film applied (control)
Number of subjects: 25
Study 38238350 — intervention group
Group type: EXPERIMENTAL
Intervention: Service dog (veterans n=88, partners n=46)
Number of subjects: 245
Study 38238350 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group: n=73, partners n=38)
Number of subjects: 245
Study 38238599 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent CC screening
Number of subjects: 753
Study 38238599 — intervention group
Group type: COMPARATOR
Intervention: Infrequent CC screening
Number of subjects: 753
Study 38238620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase (TNK) plus Dl-3-n-Butylphthalide (NBP)
Number of subjects: 100
Study 38238620 — intervention group
Group type: COMPARATOR
Intervention: Dl-3-n-Butylphthalide (NBP)
Number of subjects: 100
Study 38238616 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic CD19-specific CAR-NK cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15)
Number of subjects: 37
Study 38238666 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative nadir platelet count ≤ 99 × 10^9/L
Number of subjects: 113
Study 38238686 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified care pathway (intervention group)
Number of subjects: 200
Study 38238686 — intervention group
Group type: COMPARATOR
Intervention: Usual care pathway (control group)
Number of subjects: 200
Study 38238707 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) at age 6 to 9 years
Number of subjects: 1084
Study 38238707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport and exercise at age 9 to 11 years
Number of subjects: 1084
Study 38238707 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA at age 9 to 11 years
Number of subjects: 1084
Study 38238707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep at age 6 to 9 years
Number of subjects: 1084
Study 38238747 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate care setting based on age and severity at T1 (2015-2016)
Number of subjects: 492
Study 38238747 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate care setting based on age and severity at T2 (2020-2021)
Number of subjects: 492
Study 38238747 — intervention group
Group type: EXPERIMENTAL
Intervention: Global subjective inadequacy at T1 (2015-2016)
Number of subjects: 492
Study 38238747 — intervention group
Group type: EXPERIMENTAL
Intervention: Global subjective inadequacy at T2 (2020-2021)
Number of subjects: 492
Study 38238747 — intervention group
Group type: EXPERIMENTAL
Intervention: Undermonitoring by medical care providers at T2 (2020-2021)
Number of subjects: 492
Study 38238747 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaps in performed vs prescribed paramedical care at T2 (2020-2021)
Number of subjects: 492
Study 38238759 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory EEG-based interface using voluntary modulations of attention
Number of subjects: 7
Study 38238759 — intervention group
Group type: COMPARATOR
Intervention: Auditory BCI
Number of subjects: 7
Study 38238788 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula for predicting emphysema extent based on pulmonary function data (percent predicted forced vital capacity, percent predicted forced expiratory volume in 1 second, percent predicted carbon monoxide diffusing capacity).
Number of subjects: 76
Study 38238788 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula for predicting emphysema extent.
Number of subjects: 76
Study 38238789 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/safety pad definition
Number of subjects: 718
Study 38238789 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 pads definition
Number of subjects: 718
Study 38238789 — intervention group
Group type: EXPERIMENTAL
Intervention: ICIQ-SF score
Number of subjects: 718
Study 38238809 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (rehabilitation + optional delayed surgery)
Number of subjects: 0
Study 38238809 — intervention group
Group type: COMPARATOR
Intervention: Immediate ACL reconstruction (< 12 weeks)
Number of subjects: 0
Study 38238809 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0
Study 38238809 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 38238838 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine group (group 1)
Number of subjects: 100
Study 38238838 — intervention group
Group type: COMPARATOR
Intervention: Normal saline group (group 2)
Number of subjects: 100
Study 38239158 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 60
Study 38239158 — intervention group
Group type: COMPARATOR
Intervention: Conventional behaviour management techniques (Control)
Number of subjects: 60
Study 38239359 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (250 mg orally once daily) + Camrelizumab (200 mg)
Number of subjects: 26
Study 38239409 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study of serum metabolite levels
Number of subjects: 0
Study 38239801 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity tracker with Personal Activity Intelligence (PAI) on a mobile app
Number of subjects: 183
Study 38239801 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training (additional access)
Number of subjects: 183
Study 38239801 — intervention group
Group type: EXPERIMENTAL
Intervention: Online social support (additional access)
Number of subjects: 183
Study 38240024 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 300 mg
Number of subjects: 24
Study 38240199 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14420
Study 38240199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14420
Study 38240201 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent severe disability trajectory
Number of subjects: 3533
Study 38240201 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe to moderate disability trajectory
Number of subjects: 3533
Study 38240201 — intervention group
Group type: COMPARATOR
Intervention: No significant disability trajectory
Number of subjects: 3533
Study 38240204 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose edoxaban (15 mg once daily)
Number of subjects: 984
Study 38240204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 38240222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging (CMR)
Number of subjects: 102
Study 38240379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral vein puncture
Number of subjects: 254
Study 38240504 — intervention group
Group type: EXPERIMENTAL
Intervention: AHUP-CPR
Number of subjects: 2232
Study 38240504 — intervention group
Group type: COMPARATOR
Intervention: C-CPR
Number of subjects: 2232
Study 38240536 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine-2 receptor antagonist (SUP)
Number of subjects: 68
Study 38240536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 38240773 — intervention group
Group type: EXPERIMENTAL
Intervention: RPO-enriched biscuits
Number of subjects: 651
Study 38240773 — intervention group
Group type: COMPARATOR
Intervention: palm olein-enriched biscuits
Number of subjects: 651
Study 38240778 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN + VAN
Number of subjects: 93
Study 38240778 — intervention group
Group type: EXPERIMENTAL
Intervention: CAZ + VAN
Number of subjects: 93
Study 38240778 — intervention group
Group type: EXPERIMENTAL
Intervention: MOX
Number of subjects: 93
Study 38240778 — intervention group
Group type: EXPERIMENTAL
Intervention: NT + VRC
Number of subjects: 93
Study 38240778 — intervention group
Group type: COMPARATOR
Intervention: VRC
Number of subjects: 93
Study 38240778 — intervention group
Group type: COMPARATOR
Intervention: NT
Number of subjects: 93
Study 38240778 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC + CAZ + VAN
Number of subjects: 93
Study 38240778 — intervention group
Group type: COMPARATOR
Intervention: NT + CAZ + VAN
Number of subjects: 93
Study 38240791 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose enoxaparin 30 mg q12hours (E30q12)
Number of subjects: 20
Study 38240791 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose enoxaparin 40 mg q24hours (E40q24)
Number of subjects: 20
Study 38240791 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 5000 Units q8hours
Number of subjects: 20
Study 38240791 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 20
Study 38240843 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion (43.6% of patients)
Number of subjects: 1046
Study 38240843 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron replacement (18.9% of patients)
Number of subjects: 1046
Study 38240843 — intervention group
Group type: EXPERIMENTAL
Intervention: ESA (10.1% of patients)
Number of subjects: 1046
Study 38240843 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 replacement (5.7% of patients)
Number of subjects: 1046
Study 38240843 — intervention group
Group type: COMPARATOR
Intervention: No guideline-directed indication for transfusions (36.6% of 785 patients)
Number of subjects: 1046
Study 38240875 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 185
Study 38240916 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks
Number of subjects: 50
Study 38240916 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel/docetaxel)
Number of subjects: 50
Study 38240918 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI) tube with mechanical ventilation for four days or longer (n=57)
Number of subjects: 100
Study 38240918 — intervention group
Group type: COMPARATOR
Intervention: Control group: Patients extubated after three days or less of mechanical ventilation (n=43)
Number of subjects: 100
Study 38241047 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI alert combined with a care bundle
Number of subjects: 2208
Study 38241047 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2208
Study 38241047 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI alert
Number of subjects: 2208
Study 38241058 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH (unfractionated heparin) median dose 8000 IU; clopidogrel 600 mg
Number of subjects: 40
Study 38241058 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT >196 s at 2 h
Number of subjects: 40
Study 38241059 — intervention group
Group type: EXPERIMENTAL
Intervention: Estetrol (E4) 15 mg for 12 weeks
Number of subjects: 0
Study 38241059 — intervention group
Group type: EXPERIMENTAL
Intervention: Estetrol (E4) 2.5 mg for 12 weeks
Number of subjects: 0
Study 38241059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38241070 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric RMT system with in-app components (n=50)
Number of subjects: 100
Study 38241070 — intervention group
Group type: COMPARATOR
Intervention: Control group using RADAR-base system without additional in-app components (n=50)
Number of subjects: 100
Study 38241071 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 patients with depression and/or anxiety, assessed using the Chalder Fatigue Scale (CFQ-11) and the Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 0
Study 38241071 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 patients, assessed using the EQ-5D questionnaire
Number of subjects: 0
Study 38241071 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 patients, assessed using the 14-item Posttraumatic Stress Scale (PTSS-14)
Number of subjects: 0
Study 38241071 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 patients, examining the association between mental health symptoms and the severity of acute COVID-19
Number of subjects: 0
Study 38241126 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38241163 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) in NIHSS score 9-12 group
Number of subjects: 1776
Study 38241163 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) in NIHSS score 6-8 group
Number of subjects: 1776
Study 38241163 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) in NIHSS score 13-16 group
Number of subjects: 1776
Study 38241163 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1776
Study 38241166 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle-promoting practice implementation support from managers
Number of subjects: 42
Study 38241166 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from managers to health care professionals
Number of subjects: 42
Study 38241166 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of managers at all levels
Number of subjects: 42
Study 38241247 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide (1 hour at 50% concentration) plus intravenous saline (100mL)
Number of subjects: 40
Study 38241247 — intervention group
Group type: COMPARATOR
Intervention: Inhaled oxygen (1 hour at 50% concentration) plus intravenous midazolam (0.02 mg/kg in 100mL, up to 2mg)
Number of subjects: 40
Study 38241247 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide
Number of subjects: 40
Study 38241247 — intervention group
Group type: COMPARATOR
Intervention: Inhaled oxygen plus intravenous midazolam
Number of subjects: 40
Study 38241252 — intervention group
Group type: EXPERIMENTAL
Intervention: F64L genotype
Number of subjects: 141
Study 38241252 — intervention group
Group type: EXPERIMENTAL
Intervention: I68L genotype
Number of subjects: 141
Study 38241252 — intervention group
Group type: EXPERIMENTAL
Intervention: I107V genotype
Number of subjects: 141
Study 38241252 — intervention group
Group type: EXPERIMENTAL
Intervention: S77Y genotype
Number of subjects: 141
Study 38241252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed phenotype
Number of subjects: 141
Study 38241265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention for frailty reduction over 24 weeks
Number of subjects: 68
Study 38241286 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38241321 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-RVT assessment before hepatectomy
Number of subjects: 3402
Study 38241321 — intervention group
Group type: COMPARATOR
Intervention: 2D imaging assessment before hepatectomy
Number of subjects: 3402
Study 38241354 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation (LT) for HCC
Number of subjects: 569
Study 38241451 — intervention group
Group type: EXPERIMENTAL
Intervention: Education via videoconferencing at home (4 video conference sessions, educational booklets provided)
Number of subjects: 60
Study 38241451 — intervention group
Group type: COMPARATOR
Intervention: Control group (face-to-face education)
Number of subjects: 60
Study 38241489 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss attempts
Number of subjects: 0
Study 38241489 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-related stress
Number of subjects: 0
Study 38241489 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image
Number of subjects: 0
Study 38241600 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy chemoradiotherapy
Number of subjects: 158
Study 38241600 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy chemoradiotherapy
Number of subjects: 158